The Filing Desk

Syndax Pharmaceuticals

SNDX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

SNDX · Last close · November 13, 2026
$9.45
Value Syndax Pharmaceuticals yourself

Syndax Pharmaceuticals' revenue rose 627.8% to $172 million in fiscal 2025. Its operating margin was −158.4%, up from −1,434.4% a year earlier. Free cash flow was −$323 million. The diluted share count rose 1.2%.

Syndax Pharmaceuticals, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001193125-26-076536 Updated
Revenue
$172M
627.8%
Operating margin
−158.4%
1276.0 pts
Net income
−$285M
 
Free cash flow
−$323M
 
Return on equity
−161.8%
86.1 pts
Market cap
$849M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Return on capital for fiscal 2025 is blank: invested capital is small next to total assets (cash nearly matches equity and debt), so the ratio isn't meaningful. Piotroski F-score for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Syndax Pharmaceuticals does

Syndax is a drug company that sells two cancer medicines and is testing more uses for them. Revuforj (revumenib) treats certain relapsed or hard-to-treat acute leukemias, in people with a KMT2A gene change or with an NPM1 gene mutation. Niktimvo (axatilimab-csfr) treats chronic graft-versus-host disease, a condition in which donor cells attack a transplant patient's body, after other treatments have failed. The U.S. Food and Drug Administration approved Niktimvo in August 2024, Revuforj in November 2024, and a second use for Revuforj in October 2025.

Syndax earns money by selling Revuforj itself in the United States. It runs the sales and further development of Revuforj, and works with its partner Incyte on Niktimvo. It licensed the worldwide rights to both medicines from other companies. It describes both as the first of their kind.

The company is also running trials of revumenib with standard treatments in newly diagnosed patients, studying it in a bone marrow disease called myelofibrosis, and testing axatilimab in a lung disease. It plans to license or buy more drug candidates and says it may sell Revuforj outside the United States, alone or with partners.

Its biggest risks, as it describes them

  • It relies on two approved medicines, so weak sales or safety problems with either would hurt it.
  • Its trials of new uses for its medicines may fail or be delayed, and regulators may not approve them.
  • It depends on its partner Incyte for Niktimvo and on licenses from other companies for its medicines.
  • Competing medicines, including other drugs aimed at the same target, could take away patients.
  • It may need to raise more money, and it depends on outside makers and suppliers.
From Syndax Pharmaceuticals's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Syndax Pharmaceuticals lost money in fiscal 2025: a net loss of $285 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments440476571573394
Debt incl. finance leases——0669—
Net debt (negative means net cash)——−57196—
Net debt to EBITDA—————
Debt to equity——0.0x2.3x—
Interest coverage13.8x−48.4x−1,105.5x−339,672.0x−45,514.0x
Current ratio21.7x16.9x10.0x5.8x4.4x
Quick ratio21.7x16.9x10.0x5.8x4.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Syndax Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Syndax Pharmaceuticals shares on the open market, and 3 insiders sold $2.7 million, $2.0 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 8, 2026Michael A MetzgerChief Executive Officer, DirectorSold plan32,375$24.24$784,770Form 4
Jun 12, 2026Nicholas A.J. BotwoodHead of R&D, CMOSold plan31,235$18.14$566,603Form 4
Jun 11, 2026Nicholas A.J. BotwoodHead of R&D, CMOSold plan34,280$18.00$617,040Form 4
Jun 1, 2026Michael A MetzgerChief Executive Officer, DirectorSold6,847$18.99$130,025Form 4
Jun 1, 2026Keith A. GoldanChief Financial OfficerSold1,177$18.99$22,351Form 4
Feb 9, 2026Michael A MetzgerChief Executive Officer, DirectorSold17,159$21.03$360,854Form 4
Feb 9, 2026Keith A. GoldanChief Financial OfficerSold3,410$21.03$71,712Form 4
Feb 6, 2026Michael A MetzgerChief Executive Officer, DirectorSold7,412$20.62$152,835Form 4
Feb 6, 2026Keith A. GoldanChief Financial OfficerSold2,082$20.62$42,931Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score—2 of 8—
Rule of 40——440.3%
Altman Z''8.19−3.43−7.54
Accruals ratio−8.8%−6.6%6.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assets—Fail—
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailPassPass
F-score—2 of 8—
Companies that report no gross profit are scored on the other eight.

Compare

Put Syndax Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Syndax PharmaceuticalsFY25627.8%−158.4%−187.5%———
Stoke TherapeuticsFY25404.5%−11.2%24.4%———Compare
LiquidiaFY251,031.2%−32.5%−25.3%———Compare
Rhythm PharmaceuticalsFY2545.8%−101.2%−61.5%——6Compare
IDEAYA BiosciencesFY253,024.4%−72.8%−33.6%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue122221400024172
Revenue growth94.6%72.8%−28.0%0.0%0.0%9,109.6%−100.0%——627.8%
Gross profit——————————
Research and development324860435088118163242259
Operating income−44−62−76−58−7126−152−230−340−273
Net income−44−61−74−56−7325−149−209−319−285
Diluted EPS (US$)−3.22−2.90−2.92−1.84−1.870.46−2.46−2.98−3.72−3.29
Diluted shares (millions)15212530415461708687
Cash flow
Cash from operations−35−47−68−51−7129−134−161−275−323
Capital expenditure000—000000
Free cash flow−35−47−69—−7129−134−161−275−323
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation566691316314348
Balance sheet at fiscal year end
Cash and short-term investments1051308160293440476571573394
Debt incl. finance leases———————0669—
Total assets1091378464301450497613725530
Total liabilities2533313248413059437465
Shareholders' equity84104533225240846755428865
Margins and ratios
Gross margin——————————
Operating margin−3,587.4%−2,939.0%−5,001.7%−3,792.9%−4,708.2%18.8%——−1,434.4%−158.4%
Net margin−3,645.2%−2,884.3%−4,875.5%−3,694.6%−4,822.5%17.8%——−1,346.1%−165.6%
Free cash flow margin−2,903.1%−2,251.2%−4,529.9%—−4,697.4%20.8%——−1,160.9%−187.5%
Rule of 40 (growth + FCF margin)−2,808.5%−2,178.4%−4,557.9%—−4,697.4%9,130.3%———440.3%
Return on capital————————−145.8%—
Return on equity—−64.5%−94.0%−132.4%−51.6%7.5%−34.1%−41.0%−75.7%−161.8%
Return on assets−44.7%−49.4%−66.9%−76.0%−40.2%6.6%−31.5%−37.7%−47.7%−45.5%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Syndax Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Syndax Pharmaceuticals.